|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-18
|
|
pubmed:abstractText |
Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/APOA5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Apoa5 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins A,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/GPI-HBP1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, VLDL,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Lipoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1524-4636
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2504-9
|
|
pubmed:dateRevised |
2011-1-10
|
|
pubmed:meshHeading |
pubmed-meshheading:20966404-Animals,
pubmed-meshheading:20966404-Apolipoproteins,
pubmed-meshheading:20966404-Apolipoproteins A,
pubmed-meshheading:20966404-Binding Sites,
pubmed-meshheading:20966404-Biological Markers,
pubmed-meshheading:20966404-Disease Models, Animal,
pubmed-meshheading:20966404-Dose-Response Relationship, Drug,
pubmed-meshheading:20966404-Down-Regulation,
pubmed-meshheading:20966404-Heparin,
pubmed-meshheading:20966404-Humans,
pubmed-meshheading:20966404-Hypertriglyceridemia,
pubmed-meshheading:20966404-Hypolipidemic Agents,
pubmed-meshheading:20966404-Injections, Intravenous,
pubmed-meshheading:20966404-Lipoproteins, HDL,
pubmed-meshheading:20966404-Lipoproteins, VLDL,
pubmed-meshheading:20966404-Male,
pubmed-meshheading:20966404-Mice,
pubmed-meshheading:20966404-Mice, Knockout,
pubmed-meshheading:20966404-Mutagenesis, Site-Directed,
pubmed-meshheading:20966404-Mutation,
pubmed-meshheading:20966404-Receptors, Lipoprotein,
pubmed-meshheading:20966404-Recombinant Proteins,
pubmed-meshheading:20966404-Time Factors,
pubmed-meshheading:20966404-Triglycerides
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.
|
|
pubmed:affiliation |
Center for Prevention of Obesity, Cardiovascular Disease and Diabetes, Children's Hospital Oakland Research Institute, Oakland, Calif, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
